Celldex Therapeutics, Inc. (CLDX)
After hours:
| Previous close | 43.86 |
| Open | 44.90 |
| Bid | 44.50 x 100 |
| Ask | 44.75 x 100 |
| Day's range | 43.10 - 46.83 |
| 52-week range | 22.11 - 53.18 |
| Volume | |
| Avg. volume | 662,779 |
| Market cap | 2.937B |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.86 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.78 |
GlobeNewswireCelldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU -- Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihista
GuruFocus.comInsider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...
On June 7, 2024, Diane Young, Senior Vice President and Chief Medical Officer of Celldex Therapeutics Inc (NASDAQ:CLDX), sold 45,000 shares of the company.
- GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage b
